Hemophagocytic Lymphohistiocytosis clinical trials at UCLA
2 in progress, 1 open to eligible people
PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
open to eligible people ages 6 months to 80 years
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis and adult onset Still's disease) or with sHLH/MAS in systemic lupus erythematous, resenting an inadequate response to high dose glucocorticoid treatment.
Los Angeles, California and other locations
ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis
Sorry, not currently recruiting here
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. ELA026 is a fully human IgG1 SIRP-directed monoclonal antibody designed to reduce the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with secondary hemophagocytic lymphohistiocytosis.
Los Angeles, California and other locations
Last updated: